Detailed mechanism of the autoxidation of N-hydroxyurea catalyzed by a superoxide dismutase mimic Mn(III) porphyrin: formation of the nitrosylated Mn(II) porphyrin as an intermediate

被引:7
作者
Kalmar, Jozsef [1 ]
Biri, Bernadett [2 ]
Lente, Gabor [1 ]
Banyai, Istvan [3 ]
Budimir, Ana [4 ]
Birus, Mladen [4 ]
Batinic-Haberle, Ines [5 ]
Fabian, Istvan [1 ]
机构
[1] Univ Debrecen, Dept Inorgan & Analyt Chem, H-4010 Debrecen, Hungary
[2] Univ Debrecen, Dept Appl Chem, H-4010 Debrecen, Hungary
[3] Univ Debrecen, Dept Colloid & Environm Chem, H-4010 Debrecen, Hungary
[4] Univ Zagreb, Fac Pharm & Biochem, Zagreb 41000, Croatia
[5] Duke Univ, Sch Med, Dept Radiat Oncol, Durham, NC 27710 USA
基金
匈牙利科学研究基金会;
关键词
SICKLE-CELL-ANEMIA; EXTRACTING EXPERIMENTAL INFORMATION; NITRIC-OXIDE; MANGANESE PORPHYRINS; LARGE MATRICES; NITROXYL HNO; HEMOGLOBIN; OXIDATION; KINETICS; SOD;
D O I
10.1039/c2dt31200j
中图分类号
O61 [无机化学];
学科分类号
070301 ; 081704 ;
摘要
The in vitro autoxidation of N-hydroxyurea (HU) is catalyzed by Mn(III)TTEG-2-PyP5+, a synthetic water soluble Mn(III) porphyrin which is also a potent mimic of the enzyme superoxide dismutase. The detailed mechanism of the reaction is deduced from kinetic studies under basic conditions mostly based on data measured at pH = 11.7 but also including some pH-dependent observations in the pH range 9-13. The major intermediates were identified by UV-vis spectroscopy and electrospray ionization mass spectrometry. The reaction starts with a fast axial coordination of HU to the metal center of Mn(III)TTEG-2-PyP5+, which is followed by a ligand-to-metal electron transfer to get Mn(II)TTEG-2-PyP4+ and the free radical derived from HU (HU.). Nitric oxide (NO) and nitroxyl (HNO) are minor intermediates. The major pathway for the formation of the most significant intermediate, the {MnNO} complex of Mn(II)TTEG-2-PyP4+, is the reaction of Mn(II)TTEG-2-PyP4+ with NO. We have confirmed that the autoxidation of the intermediates opens alternative reaction channels, and the process finally yields NO2- and the initial Mn(III)TTEG-2-PyP5+. The photochemical release of NO from the {MnNO} intermediate was also studied. Kinetic simulations were performed to validate the deduced rate constants. The investigated reaction has medical implications: the accelerated production of NO and HNO from HU may be utilized for therapeutic purposes.
引用
收藏
页码:11875 / 11884
页数:10
相关论文
共 67 条
[11]   Superoxide Dismutase Mimics: Chemistry, Pharmacology, and Therapeutic Potential [J].
Batinic-Haberle, Ines ;
Reboucas, Julio S. ;
Spasojevic, Ivan .
ANTIOXIDANTS & REDOX SIGNALING, 2010, 13 (06) :877-918
[12]   Unexpected adduct formation in the reaction of peroxomonosulfate ion with the tris-(2,2′-bipyridine)iron(II) and tris-(1,10-phenanthroline)iron(II) complexes [J].
Beller, Gabor ;
Batki, Gabriella ;
Lente, Gabor ;
Fabian, Istvan .
JOURNAL OF COORDINATION CHEMISTRY, 2010, 63 (14-16) :2586-2597
[13]   HYDROXYUREA THERAPY [J].
BOYD, AS .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1991, 25 (03) :518-524
[14]   A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy [J].
Bridges, KR ;
Barabino, GD ;
Brugnara, C ;
Cho, MR ;
Christoph, GW ;
Dover, G ;
Ewenstein, BM ;
Golan, DE ;
Guttmann, CRG ;
Hofrichter, J ;
Mulkern, RV ;
Zhang, B ;
Eaton, WA .
BLOOD, 1996, 88 (12) :4701-4710
[15]   Water exchange rates of water-soluble manganese(III) porphyrins of therapeutical potential [J].
Budimir, Ana ;
Jozsef Kalmar ;
Istvan Fabian ;
Lente, Gabor ;
Istvan Banyai ;
Batinic-Haberle, Ines ;
Birus, Mladen .
DALTON TRANSACTIONS, 2010, 39 (18) :4405-4410
[16]  
Budimir A, 2009, CROAT CHEM ACTA, V82, P807
[17]   Differential regulation of DNA synthesis by nitric oxide and hydroxyurea in vascular smooth muscle cells [J].
Bundy, R ;
Marczin, N ;
Chester, AH ;
Yacoub, N .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1999, 277 (05) :H1799-H1807
[18]   Nitric oxide generation from hydroxyurea: significance and implications for leukemogenesis in the management of myeloproliferative disorders [J].
Burkitt, MJ ;
Raafat, A .
BLOOD, 2006, 107 (06) :2219-2222
[19]   EFFECT OF HYDROXYUREA ON THE FREQUENCY OF PAINFUL CRISES IN SICKLE-CELL-ANEMIA [J].
CHARACHE, S ;
TERRIN, ML ;
MOORE, RD ;
DOVER, GJ ;
BARTON, FB ;
ECKERT, SV ;
MCMAHON, RP ;
BONDS, DR ;
ORRINGER, E ;
JONES, S ;
STRAYHORN, D ;
ROSSE, W ;
PHILLIPS, G ;
PEACE, D ;
JOHNSONTELFAIR, A ;
MILNER, P ;
KUTLAR, A ;
TRACY, A ;
BALLAS, SK ;
ALLEN, GE ;
MOSHANG, J ;
SCOTT, B ;
STEINBERG, M ;
ANDERSON, A ;
SABAHI, V ;
PEGELOW, C ;
TEMPLE, D ;
CASE, E ;
HARRELL, R ;
CHILDERIE, S ;
EMBURY, S ;
SCHMIDT, B ;
DAVIES, D ;
KOSHY, M ;
TALISCHYZAHED, N ;
DORN, L ;
PENDARVIS, G ;
MCGEE, M ;
TELFER, M ;
DAVIS, A ;
CASTRO, O ;
FINKE, H ;
PERLIN, E ;
SITEMAN, J ;
GASCON, P ;
DIPAOLO, P ;
GARGIULO, S ;
ECKMAN, J ;
BAILEY, JH ;
PLATT, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (20) :1317-1322
[20]   Hydroxyurea and sickle cell anemia - Clinical utility of a myelosuppressive ''switching'' agent [J].
Charache, S ;
Barton, FB ;
Moore, RD ;
Terrin, ML ;
Steinberg, MH ;
Dover, GJ ;
Ballas, SK ;
McMahon, RP ;
Castro, O ;
Orringer, EP ;
Jones, S ;
Strayhorn, D ;
Rosse, W ;
Phillips, G ;
Peace, D ;
JohnsonTelfair, A ;
Milner, P ;
Kutlar, A ;
Tracy, A ;
Allen, GE ;
Moshang, J ;
Steinberg, M ;
Anderson, A ;
Sabahi, V ;
Pegelow, C ;
Temple, D ;
Case, E ;
Harrell, R ;
Embury, S ;
Schmidt, B ;
Koshy, M ;
TalischyZahed, N ;
Dorn, L ;
Pendarvis, G ;
McGee, M ;
Telfer, M ;
Davis, A ;
Finke, H ;
Perlin, E ;
Siteman, J ;
Gascon, P ;
diPaolo, P ;
Gargiulo, S ;
Eckman, J ;
Bailey, JH ;
Platt, A ;
Waller, L ;
Ramirez, G ;
Knors, V ;
Hernandez, S .
MEDICINE, 1996, 75 (06) :300-326